Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have stable body weight for the past 12 weeks prior to screening~2. Have a body mass index (BMI) ≥24 kilograms per meter squared (kg/m²) with complication, or BMI≥28 kg/m²,inclusive at screening~3. Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff~Exclusion Criteria:~1. Have a diagnosis of type 2 diabetes~2. Have received prescription drugs or over the counter drugs that promote weight loss in the past 3 months prior to screening~3. Previous treatment with a GLP-1 (glucagon-like peptide 1) receptor agonists or GCG(glucagon)receptor agonists before.~4. Surgical treatment for obesity~5. Past or current chronic or idiopathic pancreatitis, or any of the following: -amylase or lipase above 2 times UNR (upper normal range), triglycerides above 500 mg/dL~6. Have other medical conditions or medical history that make participation in the study unsafe or which may interfere in the interpretation of the results of the study~7. Unwilling to comply with smoking and alcohol restrictions during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI362 (Type: EXPERIMENTAL): Participants received dose 1 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 2 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 3 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 4 level of IBI362 administered as multiple subcutaneous doses.~Participants received dose 5 level of IBI362 administered as multiple subcutaneous doses.
- placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo dose regiments by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).